Sydney Jennings

Highlights include widespread lack of structured menopause education in primary care residency programs, sleep benefits of elinzanetant, and more.

CTAD 2025: Early, continued treatment with lecanemab may delay Alzheimer disease progression by up to 8.3 years; SC dosing demonstrates bioequivalence.

The updated guideline from the American Cancer Society introduces self-collection for HPV testing and new exit criteria to enhance accessibility.

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Discover key insights from the latest Weekly Dose Podcast, covering cognitive health, reproductive care, and Alzheimer diagnostics for primary care clinicians.

New data reveals lecanemab's significant impact on amyloid-beta protofibrils in Alzheimer disease, showcasing its potential to slow disease progression.

Your daily dose of the clinical news you may have missed.

Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.

New findings reveal etalanetug significantly reduces tau biomarkers in Alzheimer’s patients, paving the way for innovative blood-based assessments of tau pathology.

New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.

Your daily dose of the clinical news you may have missed.

Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.

Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.

Your daily dose of the clinical news you may have missed.

Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.

Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.

Your daily dose of the clinical news you may have missed.

Two new Cochrane reviews confirm HPV vaccines significantly reduce cervical cancer risk, especially when given before age 16, with no serious safety concerns.

A recent meta-analysis reveals that two-thirds of pregnancies experience unhealthy weight gain, highlighting risks for mothers and babies.

Your daily dose of the clinical news you may have missed.

Lisa Larkin, MD, discusses how social media is driving menopause awareness and why primary care physicians must educate themselves to meet patient demand.

New research reveals that caffeinated coffee significantly reduces the recurrence of atrial fibrillation, challenging long-held medical advice.

Your daily dose of the clinical news you may have missed.

Larkin Larkin, MD, reviews treatment options for VMS, comparing hormone therapy effectiveness with antidepressants and new neurokinin antagonists.

Results showed that Pfizer’s mRNA vaccine cut influenza-like illness by 34.5% compared with a standard influenza vaccine.

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

FDA approves Dexcom Smart Basal, a groundbreaking CGM-integrated insulin dosing optimizer, enhancing diabetes management for adults with Type 2 diabetes.

Real-world data from 20 000 patients demonstrate significantly higher adherence rates with Shield blood test vs colonoscopy and stool-based screening methods.

Study author Daniel Jiang, MD, PhD, discusses data linking hormone therapy to increased autoimmune disease risk in postmenopausal women and clinical implications.

Northwestern University unveils a groundbreaking online tool that helps younger adults understand their 30-year cardiovascular disease risk through percentile rankings.